Inactive Instrument

Achillion Pharmaceuticals, Inc.

US00448Q2012

Biotechnology & Medical Research

Achillion Pharmaceuticals, Inc. Announces Resignation of Dennis Liotta as Class I Director

June 09, 2015 at 01:47 am IST

Dennis Liotta, a Class I director of Achillion Pharmaceuticals, Inc. resigned from the company's Board of Directors.

Latest news about Achillion Pharmaceuticals, Inc.

Achillion Pharmaceuticals, Inc.(NasdaqGS:ACHN) dropped from S&P Global BMI Index	29/20/29	CI
Achillion Pharmaceuticals, Inc.(NasdaqGM:ACHN) dropped from S&P TMI Index	29/20/29	CI
Achillion Pharmaceuticals, Inc.(NasdaqGM:ACHN) dropped from S&P Biotechnology Select Industry Index	29/20/29	CI
Achillion Pharmaceuticals, Inc. Announces Management Changes	28/20/28	CI
Achillion Pharmaceuticals, Inc.(NasdaqGS:ACHN) dropped from NASDAQ Composite Index	28/20/28	CI
Achillion Pharmaceuticals, Inc.(NasdaqGS:ACHN) dropped from NASDAQ Biotechnology Index	28/20/28	CI
Alexion Pharmaceuticals, Inc. completed the acquisition of Achillion Pharmaceuticals, Inc..	28/20/28	CI
Achillion Reports Positive Data from Phase 2 Study of Danicopan (ACH-4471) in Combination with Eculizumab in PNH Patients who Have an Inadequate Response to Eculizumab Monotherapy at the 61st American Society of Hematology Meeting	09/19/09	CI
European Medicines Agency Grants Achillion PRIME Designation to Danicopan for Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients Who Are Not Adequately Responding to a C5 Inhibitor	19/19/19	CI
Achillion Pharmaceuticals, Inc. Announces Clearance of Investigational New Drug Application for ACH-5228	11/19/11	CI
Achillion Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	08/19/08	CI
Alexion Pharmaceuticals, Inc. entered into a definitive agreement to acquire Achillion Pharmaceuticals, Inc. for approximately $880 million.	16/19/16	CI
Achillion Receives Breakthrough Therapy Designation from FDA for Danicopan for Treatment of Paroxysmal Nocturnal Hemoglobinuria	25/19/25	CI
Achillion Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	08/19/08	CI
Achillion Pharmaceuticals, Inc.'s ACH-5228 Achieves Positive Results in Phase 1 Multiple Ascending Dose Study in Healthy Volunteers	22/19/22	CI
Achillion Pharmaceuticals, Inc. Announces the Final Data Set for ACH-4471 (Newly Designated “Danicopan”) Proof of Concept Phase 2 Trial in Untreated Patients with Paroxysmal Nocturnal Hemoglobinuria	10/19/10	CI
Transcript : Achillion Pharmaceuticals, Inc. - Shareholder/Analyst Call	30/19/30
Achillion Reports Positive Interim Data for ACH-4471 Phase 2 Combination Trial with Eculizumab at The New Era of Aplastic Anemia and PNH Meeting	17/19/17	CI
Achillion Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019	09/19/09	CI
Achillion Pharmaceuticals Announces Enrollment Milestone in Phase 2 Trials for C3 Glomerulopathy	03/19/03	CI
Achillion Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 2 PNH Combination Trial	27/19/27	CI
Transcript : Achillion Pharmaceuticals, Inc. Presents at Barclays Global Healthcare Conference 2019, Mar-14-2019 10:15 AM	14/19/14
Achillion Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2018	07/19/07	CI
Achillion Pharmaceuticals, Inc. Announces Expansion into a Second Office in Blue Bell, Philadelphia	21/19/21	CI
Achillion Pharmaceuticals, Inc. Announces Management Changes, Effective as of February 11, 2019	12/19/12	CI

Chart Achillion Pharmaceuticals, Inc.

Duration

Period

More charts

Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system. The complement system is part of the human innate immune system. Its clinical compound from its complement inhibitor platform is ACH-4471. ACH-4471 is a potent and specific inhibitor of factor D, which demonstrated complete inhibition of the complement alternative pathway in human healthy volunteers in a Phase I clinical trial. The Company has discovered and advanced multiple compounds into clinical development, including sovaprevir, odalasvir, and ACH-3422 in its hepatitis C virus (HCV) program.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+15.82%	12TCr
REGENERON PHARMACEUTICALS, INC.	+20.35%	11TCr
ARGENX SE	+17.47%	2.6TCr
BIONTECH SE	-25.31%	1.94TCr
GENMAB A/S	-19.51%	1.59TCr
BEIGENE, LTD.	-19.67%	1.51TCr
WUXI APPTEC CO., LTD.	-46.87%	1.51TCr
SAREPTA THERAPEUTICS, INC.	+62.55%	1.49TCr
NEUROCRINE BIOSCIENCES, INC.	+6.34%	1.39TCr

Bio Therapeutic Drugs